118th Congress Health
H.R. 4053: Studying Suboxone Act
Introduced
- Introduced (completed)
- Passed House (not reached)
- Passed Senate (not reached)
- To the President (not reached)
- Became law (not reached)
Summary
This bill requires the Department of Health and Human Services (HHS) and the Drug Enforcement Administration (DEA) to reevaluate the scheduling of buprenorphine-naloxone combination products (e.g., suboxone) under the Controlled Substances Act. These products are used to treat opioid addictions and are currently schedule III controlled substances. (A schedule III controlled substance is a drug, substance, or chemical that has less potential for abuse than a schedule I or II substance; that has a currently accepted medical use; and that has low or moderate risk of dependence if abused.)
Specifically, the bill requires HHS to review scientific and medical evaluations relating to these products and update its scheduling recommendations accordingly. The DEA must review the recommendations of HHS and make appropriate scheduling changes.
Written by the Congressional Research Service, Library of Congress.
Roll calls
No roll call votes have been held on this bill.
Amendments
No amendments were offered to this bill.
Cosponsors
- Earl Carter R-GAOriginal
- Paul Tonko D-NY
- Marcus Molinaro R-NY
Who scored on this bill
- 1Ann Kuster SponsorDrew cross-party cosponsors, introduced2 events+6
See all scorers and every scoring event
Introductions and cosponsorships count toward weekly caps and show no points.
History
- Introduced in the House by Ann Kuster.
Show the full action history (3 actions)
- Referred to the Subcommittee on Health.
- Introduced in House
- Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.